Leukemia impact Factor

Leukemia Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 0887-6924 Leukemia Impact Score 2020-2021 The impact score(IS) 2020 of Leukemia is8.21, which is computed in 2021 as per it's definition. The impact score (IS), also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data Leukemia and Lymphoma Impact Factor 2019-2020 The impact factor (IF) 2019 of Leukemia and Lymphoma is 2.969, which is computed in 2020 as per it's definition. Leukemia and Lymphoma IF is increased by a factor of 0.3 and approximate percentage change is 11.03% when compared to preceding year 2018, which shows a rising trend The Journal of Leukemia is an academic journal - hosted by OMICS International - a pioneer in open access publishing-and is listed among the top 10 journals in Leukemia. Each year research scientists have noticed a rise in the number of congresses being held in this field

Leukemia Impact Factor IF 202020192018 - BioxBi

  1. Leukemia Research Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 0145-2126
  2. Leukemia is a peer-reviewed medical journal published by the Nature Publishing Group. It was established in 1987 by Nicole Muller-Bérat Killman and Sven-Aage Killman, and is currently edited by Professors Andreas Hochhaus and Robert Peter Gale. The journal covers research on all aspects of leukemia and has a 2019 impact factor of 8.665
  3. Five-Year Impact Factor: 2019: 2.201. To calculate the five year Impact Factor, citations are counted in 2019 to the previous five years and divided by the source items published in the previous five years. Journal Citation Reports (Clarivate Analytics, 2020) Source Normalized Impact per Paper (SNIP): 0.721 ℹ. Source Normalized Impact per.
  4. Leukemia is a peer-reviewed medical journal published by the Nature Publishing Group. It was established in 1987 by Nicole Muller-Bérat Killman and Sven-Aage Killman, and is currently edited by Professors Andreas Hochhaus and Robert Peter Gale. The journal covers research on all aspects of leukemia and has a 2019 impact factor of 8.665

Leukemia - Impact Factor, Overall Ranking, Rating, h-index

International Scientific Journal & Country Ranking. Only Open Access Journals Only SciELO Journals Only WoS Journal Leukemia Impact Factor. Lymphoma is a type of body-fluid cancerous disease that occurs when B or T lymphocytes, the white body-fluid units that form a part of the immune system and help protect the body from disease and disease. Lymphoma is a cancer of lymph tissues such as lymphocytes Treatment for your leukemia depends on many factors. Your doctor determines your leukemia treatment options based on your age and overall health, the type of leukemia you have, and whether it has spread to other parts of your body, including the central nervous system. Common treatments used to fight leukemia include: Chemotherapy

Leukemia Research is a part of Elsevier's Oncology Journal Network. With Leukemia Research indexed in Pubmed/Medline, your published article is guaranteed maximum visibility. We know speed is important. Authors submitting to the journal receive a first decision within an average of 1.91 weeks About the Journal Index Copernicus Value: 64.66 Journal of Leukemia is a peer reviewed medical journal that includes a wide range of fields in Leukemia, Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myleoid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myleloid Leukemia, Hairy Cell Leukemia, Pediatric Leukemia, Leukemia drugs, Stem Cell Transplant, Plasma cell Leukemia, Mast cell. Erythropoietin, recombinant human (rh) granulocyte colony stimulating factor (CSF), rh granulocyte macrophage CSF and rh interferon have been proven to be a clinically useful therapy. Several other..

x Hairy cell leukemia (HCL) is a B-cell lymphoproliferative disorder characterized by infiltration of the bone marrow, liver and spleen by malignant B cells with hair-like cytoplasmic projections. 1 HCL is a rare disease with an estimated incidence of 3 cases per million persons per annum in the United States (600 to 800 new cases each year). 2. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis The impact of cell-of-origin, Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations - a registry based analysis Purchase Clinical Lymphoma, Myeloma & Leukemia. ISSN 2152-2650. Impact Factor: 3.231 (2020 Leukemia publishes high quality, peer reviewed research that covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance. Topics of interest include oncogenes, growth factors, stem cells, leukemia genomics, cell cycle, signal transduction. Chronic lymphocytic leukemia (CLL) is a clonal malignancy of mature B cells that displays immense clinical heterogeneity as reflected by the observation that many patients have an indolent disease that will not require intervention for many years while others will present with an aggressive and symptomatic leukemia requiring immediate treatment

Leukemia and Lymphoma - Impact Factor, Overall Ranking

Journal of leukemia. Abbreviation: J Leuk (Los Angel) ISSN: 2329-6917 (Electronic) 2329-6917 (Linking CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA AUTHOR INFORMATION PACK TABLE OF CONTENTS. XXX. • Description • Impact Factor • Abstracting and Indexing • Editorial Board • Guide for Authors p.1 p.1 p.2 p.2 p.5 ISSN: 2152-2650 DESCRIPTION. Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes origina Browse the list of issues and latest articles from Leukemia & Lymphoma. List of issues Latest articles Partial Access; Volume 62 2021 Volume 61 2020 Volume 60 2019 Volume 59 2018 Volume 58 2017 Volume 57 2016 Volume 56 2015 Volume 55 2014 Volume 54 2013 Volume 53 2012 Volume 52 2011 Volume 51 201

Updated List of High Journal Impact Factor Leukemia Journal

Hematology and Leukemia is an Open Access (Gold OA), peer reviewed, international online publishing journal, which aims to publish premier papers on all the related areas of advanced research carried on in its field. Hematology and Leukemia includes the study of all the types of blood cells, the blood-forming organs, and study of etiology, diagnosis, treatment, prognosis, prevention of blood. Clinical Lymphoma, Myeloma & Leukemia | Citations: 1,092 | Read 1100 articles with impact on ResearchGate, the professional network for scientists According to the Journal Citation Reports, the journal has a 2014 impact factor of 2.891

Leukemia Research and Treatment has ceased publication and is no longer accepting submissions. All previously published articles are available through the Table of Contents. The journal is archived in Portico and via the LOCKSS initiative, which provides permanent archiving for electronic scholarly journals. Go to Table of Contents Advances in Leukemia Research and Treatment is an open access, peer reviewed journal that publishes comprehensive research focusing upon the cancers of the bone marrow and blood. The journal comprehends novel research updates covering types, symptoms, causes, diagnosis, staging, treatment, and chemotherapy Leukemia Impact Factor Leukemia is a malignancy of cellular component in the blood and bone marrow. It is mainly related to the blood cells such as White blood cells which includes blood disorders in the blood cells and the symptoms are exposed in the immune system of the person which weakens the immune system of the person resulting in the. What Are the Risk Factors for Chronic Lymphocytic Leukemia? A risk factor is something that affects a person's chance of getting a disease like cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person's age or family history, can't be changed Prevention methods and risk factors. Most often, leukemia occurs in children and elderly people; however scientists do not know exactly what the causes of leukemia are. Still, some factors that may increase the risk of leukemia are determined (Mughal et al., 2009): Effects of large doses of radiation

About 1000 Illinoisans will die of leukemia in 2008. What are the Causes and Risk Factors of Leukemia? The exact cause of leukemia is not known. Studies have found the following risk factors for leukemia. Radiation: People exposed to very high levels of radiation are much more likely to develop leukemia. These high levels of radiation may have. Risk factors. Factors that may increase your risk of acute myelogenous leukemia (AML) include: Increasing age. The risk of acute myelogenous leukemia increases with age. Acute myelogenous leukemia is most common in adults age 65 and older. Your sex. Men are more likely to develop acute myelogenous leukemia than are women. Previous cancer treatment

Leukemia Research Impact Factor IF 202020192018 - BioxBi

  1. Leukemia is a cancer of the blood and bone marrow. In simple terms, cancer is defined as the uncontrolled growth of abnormal cells. Cancer can develop anywhere in the body. In leukemia, this rapid, out-of-control growth of abnormal cells takes place in the bone marrow of bones. These abnormal cells then spill into the bloodstream
  2. Leukemia is a cancer of the blood cells. Get the statistics on survival rates, find out the most common symptoms, diagnostic options, and treatments
  3. Journal Impact Factor List 2021. Here is the latest Impact Factor List of 2021 provided by the Journal Citation Report (JCR). It contains over 12000 Journals. JCR was earlier published as Science Citation Index, and now it is published by Clarivate Analytics, a Web of Science Group. Impact Factor Calculation

I. Forms of Leukemia. More specifically, alcohol consumption is not a risk factor for any of the various forms of leukemia: Acute lymphocytic leukemia (ALL) The most common form of leukemia in young children but also affects adults, especially those age 65 and older. Acute myleoid leukemia (AML) This form of leukemia occurs most often in adults The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the. Leukemia is a type of cancer that affects the body's blood-forming cells in the bone marrow and lymphatic system. It can take one of several forms and spread at different rates, but most types of leukemia disrupt the production of healthy white blood cells that are designed to multiply, fight infections and die off Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, with an estimated 21,000 new cases diagnosed in 2018. The disease is virtually unheard of in children and it primarily affects older adults. Almost 90% of new cases are in people age 55 and older, while the average age at the time of diagnosis is 72 Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Watanabe Y (1), Hashimoto S, Kakita A, Takahashi H, Ko J, Mizuno M, Someya T, Patterson PH, Nawa H. Author information: (1)Division of Molecular Neurobiology, Brain Research Institute, Niigata University, Asahimachi-dori 1-757, Niigata 951-8585, Japan

Leukemia Impact-Faktor IF 2020-2021 Analyse, Trend

  1. Leukemia Impact Factor, IF, number of article, detailed information and journal factor. Particularly, the expression of these genes has been proposed as a driving force for tumorigenesis and the initiation of metastasis. Many people with one or Family history. Normally, journals with higher impact factors are often deemed to have more.
  2. Leukemia. Leukemia is a type of cancer found in your blood and bone marrow and is caused by the rapid production of abnormal white blood cells. These abnormal white blood cells are not able to fight infection and impair the ability of the bone marrow to produce red blood cells and platelets. Leukemia can be either acute or chronic
  3. Superfund Research Program Leukemia (impact factor: 9.944) 2019. de Smith AJ, Walsh KM, Morimoto L, Francis SS, Hansen HM, Jeon S, Gonseth S, Chen M, Sun H, Luna.
  4. g cells (and therefore sometimes referred to as blood cancer).; While the exact cause(s) of leukemia is not known, risk factors have been identified, including radiation exposure, certain chemotherapy for cancer, smoking, family history of leukemia, and exposure to certain chemicals such as benzene.; Common symptoms of chronic or acute leukemia may.

Shop and Discover over 51,000 Books and Journals - Elsevie

  1. Jul 12, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry Leukemia Cancer Market report 2021..
  2. Childhood leukemia, the most common type of cancer in children and teens, is a cancer of the white blood cells.Abnormal white blood cells form in the bone marrow. They quickly travel through the.
  3. We evaluated the impact of salvage regimens and allogeneic hematopoietic cell transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between 1993 and 2009, 3324.
  4. The treatment of acute lymphoblastic leukemia (ALL) in patients older than 70 is extremely challenging with dismal outcome. Allogeneic stem cell transplantation (alloHCT) has seen many advancements in the last decades showing benefits in younger ALL patients, but this treatment modality is decreasingly used with increasing age due to high treatment-related mortality. We identified 84 ALL.
  5. Superfund Research Program. Many SRP scientists have published their findings in high-impact journals - those considered to be highly influential in their fields. A journal's impact factor is a measure of the frequency with which an average article in a journal has been cited in a particular year
  6. imal residual disease Montserrat Hoyos Spanish CETLAM Group Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona Spanish Cancer Network (RTICC), Institut d'Investigació Biomèdica Sant Pau, Barcelona, Spai
  7. Several forms of childhood leukemia exist, and many factors impact the outlook. Early diagnosis and prompt treatment can improve outcome. Talk to your child's doctor if you're concerned about.

1. Cancer. 2012 May 1;118(9):2420-3. doi: 10.1002/cncr.26557. Epub 2011 Sep 16. Impact of residual normal metaphases in core binding factor acute myeloid leukemia Clinical Impact of Percentage of Natural Killer Cells and Natural Killer-Like T Cell Population in Acute Myeloid Leukemia The Impact of Preoperative Intravenous Iron Therapy on Perioperative Outcomes in Cardiac Surgery: A Systematic Review Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizuma 2020 Impact Factor: 9.941 Submission > Acceptance: 52 days. driven immune-intervention after allogeneic hematopoietic stem cell transplantation for high-risk chronic lymphocytic leukemia: results of a prospective multicenter tria

Clinical Lymphoma Myeloma and Leukemia

We studied 351 patients with smoldering multiple myeloma (SMM) in whom the underlying primary molecular cytogenetic subtype could be determined based on cytoplasmic immunoglobulin fluorescent in. Purpose This study aims to evaluate the quality of life (QoL) of chronic myeloid leukemia (CML) patients prescribed with nilotinib as a second-line therapy and explores the influential factors. Methods A multicenter retrospective survey was conducted via face-to-face interviews based on the EORTC QLQ-C30 questionnaire. A total of 121 adult CML patients resistant to imatinib and used nilotinib. Childhood leukemia survivors are at risk, to some degree, for several possible late effects of their treatment. This risk depends on a number of factors, such as the type and subtype of leukemia, the type and doses of treatments they received, and the age of the child at the time of treatment Reduced-intensity therapy for pediatric lymphoblastic leukemia: impact of residual disease early in remission induction Clinical Trials & Observations of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 11 Prognosis Factors for Childhood Leukemia. Prognosis factors are a series of measurements that your child's oncology team may use to estimate the degree of risk posed by the cancer and to determine the most promising treatment plan. There are several key prognosis factors that oncologists use when dealing with a leukemia diagnosis

The first paper, titled PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress, takes a look at the effect of inflammation on the transcription factor PU.1 and its effect on the production of hematopoietic stem cells (HSCs), or the immature cells found in the bone marrow that can turn into blood cells, according to the study author James Chavez, BS Cancer, an international interdisciplinary journal of the American Cancer Society, publishes high-impact, peer-reviewed original articles and solicited content on the latest clinical research findings.Each issue of Cancer strives to be comprehensive, spanning the breadth of oncology disciplines and providing something for everyone involved in cancer research, risk reduction, treatment, and. T cell acute lymphoblastic leukemia (T-ALL) is an immature hematopoietic malignancy driven mainly by oncogenic activation of NOTCH1 signaling 1.In this study we report the presence of loss-of.

Impact Factor List 2012 | 2013| 2011 | 2010 | 200 Chronic lymphocytic leukemia (CLL) is a cancer that affects a type of white blood cell called a lymphocyte. Lymphocytes help your body fight infection. They're made in the soft center of your. Two recent collaborative publications by CU Cancer Center members provide insights into how chronic inflammation can serve as a key factor in the development of leukemia and other blood cancers The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses to IM. The objective of this study was to correlate the expression of e14a2 or e13a2 to clinical characteristics.

57. Wahlin A, Hörnsten P, Jonsson H. Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy. Eur J Haematol (1991) 46(4):240-7. doi: 10.1111/j.1600-0609.1991.tb00547.x. CrossRef Full Text | Google Schola Allogeneic hematopoietic cell transplantation (HCT) is an effective post-remission consolidation treatment, potentially curative, in patients with acute myeloid leukemia (AML) [1]. Since the first report of a successful bone marrow transplant in 1957, there has been a steady increase in the numbers of patients receiving HCT for AML [2]

Leukemia (journal) - Wikipedi

The Mediterranean Journal of Hematology and Infectious Diseases has been founded by Giuseppe Leone, Professor of Hematology at the Catholic University of Rome in 2009, with the collaboration of Prof. Eligio Pizzigallo, Infectivologist, and Luigi Maria Larocca, Pathologist. Read More positive regulation of transcription by RNA polymerase II Source: NTNU_SB. Inferred from direct assay i. DNA-binding and transcriptional regulatory properties of hepatic leukemia factor (HLF) and the t (17;19) acute lymphoblastic leukemia chimera E2A-HLF. Hunger S.P., Brown R., Cleary M.L The impact of NBFs (marital status, insurance status, county-level income, and education) on survival was assessed along with biological factors (disease subtype, sex, age, and race/ethnicity) using a cohort of patients aged 19 to 64 years who were diagnosed with AML between 2007 and 2011 and reported to the Surveillance, Epidemiology, and End.

The pathogenesis and the impact of therapy on thrombin activation in children with acute lymphoblastic leukemia (ALL) are unknown. Steroids may contribute to ALL‐associated thrombosis. We explored the hemostatic effects of methylprednisolone monotherapy (MpMT) (32 mg/m 2 /day IV × 3 days) in children with newly diagnosed ALL Wagner K, Damm F, Göhring G, et al. Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor Certain factors affect prognosis (chance of recovery) and treatment options. Adult acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets. Adult acute myeloid leukemia (AML) is a cancer of the blood and bone marrow The global leukemia market will grow from USD 13.21 billion in 2021 to reach USD 19.52 billion in 2026, with a CAGR of 6.52% from 2021 to 2026 Acute myeloid leukemia (AML) is a type of cancer that starts from cells that are supposed to grow into different types of blood cells. Most often, AML starts in early forms of white blood cells. AML is fast growing. The leukemia cells enter the blood quickly and sometimes can spread to the liver, spleen, central nervous system (brain and spinal.

Journal Impact Factor List 2021. Here is the latest Impact Factor List of 2021 provided by the Journal Citation Report (JCR). It contains over 12000 Journals. JCR was earlier published as Science Citation Index, and now it is published by Clarivate Analytics, a Web of Science Group. Impact Factor Calculation Leukemia is a cancer of blood or blood-forming cells (and therefore sometimes referred to as blood cancer).; While the exact cause(s) of leukemia is not known, risk factors have been identified, including radiation exposure, certain chemotherapy for cancer, smoking, family history of leukemia, and exposure to certain chemicals such as benzene.; Common symptoms of chronic or acute leukemia may.

Clinical Lymphoma Myeloma & Leukemia Impact Factor, IF, number of article, detailed information and journal factor. ISSN: 2152-2650 Chemotherapy (chemo) is the use of drugs to treat cancer. Chemo drugs travel through the bloodstream to reach cancer cells all over the body. This makes chemo useful for cancers such as leukemia that has spread throughout the body. Chemo is the main treatment for just about all people with acute lymphocytic leukemia (ALL) American Cancer Society 4-year grant funds deeper look at risk factors associated with oil and gas development, and childhood leukemia Jun 25, 2021 The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has approved funding for 42 research grants nationwide totaling $33.8M. An aggregate journal impact factor of 1.0 implies that the articles in the subject category published in recent two years have been cited once on an average. The median Impact factor is the median value of all journals impact factors in the subject category. The journal impact factor extenuates the significance of absolute citation frequencies Blood Adv. 2020;4 (21):5562-5573. Gupta V, Kim S, Hu Z-H, et al. Comparison of outcomes of HCT in blast phase of BCR-ABL1 − MPN with de novo AML and with AML following MDS. Blood Adv. 2020;4 (19):4748-4757

Journal Rankings on Hematolog

  1. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116:2224-8. CAS Article Google Schola
  2. Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients' individual variability, and recurrent gene mutations are the major obstacles among many factors that impact treatment efficacy of the AML patients. With the application of cost- and time-effective next-generation sequencing (NGS.
  3. Prognostic impact of high ABC transporter activity in 111 adult acute myeloid leukemia patients with normal cytogenetics when compared to FLT3, NPM1, CEBPA and BAALC Pierre Hirsch , 1, 2 Ruoping Tang , 1, 2 Christophe Marzac , 3 Jean-Yves Perrot , 3 Fanny Fava , 1, 2 Chantal Bernard , 3 Dorota Jeziorowska , 4 Jean Pierre Marie , 1, 2 and.
  4. The good news is you don't have to do it alone - with over 50 journals, including The Lancet Oncology , Cancer Cell , European Journal of Cancer and Cancer Letters, Elsevier's Oncology Journal Network has the right fit for your paper. Best of all, our titles offer a transparent and supportive publication process that puts you and your.
  5. YEHUDA DEUTSCH, MD: Acute myeloid leukemia, or AML, is the most common form of acute leukemia in adults. There are about 20,000 new cases or diagnoses of AML each year in the United States, and this has been steadily increasing. The average or median age of patients with AML is 65 years, and as the age increases, this [disease] increases.

Leukemia Impact Factor Peer Reviewed Journal

LIF LIF interleukin 6 family cytokine [ (human)] Impact of IFN-beta and LIF overexpression on human adipose-derived stem cells properties. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway. Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of. I. Introduction. Leukemia inhibitory factor (LIF) was originally identified as a factor inducing macrophage differentiation of the murine myeloid leukemia cell line M1 (Metcalf et al., 1988).LIF induces proliferation of hematopoietic stem cells and the DA cell line (Fletcher et al., 1990; Moreau et al., 1988).Evidence of broad actions of LIF have recently been shown, including bone. Therapy-related acute myeloid leukemia (t-AML) is a recognized clinical syndrome occurring as a complication after cytotoxic and/or radiation therapy. 1-3 At present, approximately 10% of all AMLs arise after a patient's exposure to chemotherapy and/or radiation for a primary malignancy or autoimmune disease. 4,5 Patients with t-AML are considered to have an inferior outcome compared with de. The Acute Myeloid Leukemia market is expected to register a CAGR of 14, during (the forecast period). This report focuses on Professional Global Acute Myeloid Leukemia Market 2021 volume and value. The Leukemia & Lymphoma Society has partnered with Medicine X to create. Acute Lymphoblastic Leukemia (ALL) Xplained , which uses storytelling to provide patients with a greater understanding of living with adult ALL. To learn more about the diagnosis, treatment options, monitoring, and quality of life issues associated with adult ALL, please.

Frontiers | Resistance-Associated Mutations in ChronicFrontiers | The Current Situation and Future Trend of

Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Matsuzaki A(1), Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, Kawakami K, Moritake H, Suminoe A, Okamura J Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and improvements in survival

Leukemia - Diagnosis and treatment - Mayo Clini

Leukemia & Lymphoma: Vol 62, No

List of issues Leukemia & Lymphom

Facts about LEUKEMI

Frontiers | Acute Myeloid Leukemia and the Bone MarrowFrontiers | Targeted Therapies for Pediatric AML: Gaps andFrontiers | Gene Mutations as Emerging Biomarkers andFrontiers | High Cytotoxic Efficiency of Lentivirally and